You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 7,482,323

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,482,323

Title:	Intracellular interleukin-1 receptor antagonist and uses thereof
Abstract:	Matrix metalloproteinases are major mediators of tissue destruction in various chronic inflammatory disorders. The present invention demonstrates that over-expression of intracellular isoform of IL-1 receptor antagonist confers to recipient cells resistance to signaling pathways of proinflammatory cytokines (such as tumor necrosis factor alpha and IL-1 beta) that induce matrix metalloproteinase and subsequent tissue degradation. Hence, over-expression of intracellular IL-1 receptor antagonist may inhibit tissue destruction in various inflammatory disorders such as rheumatoid arthritis, other arthritides, degenerative intervertebral disc disease and chronic skin ulcers that occurs in diabetes mellitus and bed-ridden patients.
Inventor(s):	Hasty; Karen A. (Memphis, TN), Postlethwaite; Arnold (Eads, TN), Kanangat; Sivadasan (Cordova, TN)
Assignee:	The University of Tennessee Research Foundation (Knoxville, TN)
Application Number:	11/072,170
Patent Claims:	1. A method of inhibiting tissue degradation, comprising contacting a collagenase-producing cell in a tissue with an intracellular IL-1 receptor antagonist peptide(s) selected from the group consisting of SEQ ID NOs: 13, 23, and 24; and inhibiting the expression of collagenase via said contact, thereby inhibiting tissue degradation. 2. The method of claim 1, wherein said tissue degradation is a component of chronic inflammatory disorder, wherein said chronic inflammatory disorder is arthritis, degenerative intervertebral disc disease or chronic skin ulcers. 3. A method of treating a chronic inflammatory disorder in a individual, comprising the step of administering an intracellular IL-1 receptor antagonist peptide(s) selected from the group consisting of SEQ ID NO: 13, 23, and 24 to the tissue of said individual, wherein the administration of said antagonist inhibits degradation of said tissue through inhibiting the expression of a collagenase. 4. The method of claim 3, wherein said chronic inflammatory disorder is selected from the group consisting of arthritis, degenerative intervertebral disc disease and chronic skin ulcers.

Details for Patent 7,482,323

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965	⤷ Try a Trial	2024-03-04
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.